CN113840841B - 靶向cd19的全人源抗体及其应用 - Google Patents

靶向cd19的全人源抗体及其应用 Download PDF

Info

Publication number
CN113840841B
CN113840841B CN202080037449.9A CN202080037449A CN113840841B CN 113840841 B CN113840841 B CN 113840841B CN 202080037449 A CN202080037449 A CN 202080037449A CN 113840841 B CN113840841 B CN 113840841B
Authority
CN
China
Prior art keywords
amino acid
acid sequence
cells
antibody
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080037449.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN113840841A (zh
Inventor
谭涛超
戴振宇
贾向印
魏巧娥
杨永坤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Reindeer Biotechnology Co ltd
Original Assignee
Nanjing Iaso Biotherapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Iaso Biotherapeutics Co Ltd filed Critical Nanjing Iaso Biotherapeutics Co Ltd
Priority to CN202310120560.XA priority Critical patent/CN116589579A/zh
Publication of CN113840841A publication Critical patent/CN113840841A/zh
Application granted granted Critical
Publication of CN113840841B publication Critical patent/CN113840841B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080037449.9A 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用 Active CN113840841B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310120560.XA CN116589579A (zh) 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910419089 2019-05-20
CN2019104190898 2019-05-20
PCT/CN2020/091235 WO2020233589A1 (zh) 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310120560.XA Division CN116589579A (zh) 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用

Publications (2)

Publication Number Publication Date
CN113840841A CN113840841A (zh) 2021-12-24
CN113840841B true CN113840841B (zh) 2023-03-07

Family

ID=73458076

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080037449.9A Active CN113840841B (zh) 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用
CN202310120560.XA Pending CN116589579A (zh) 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310120560.XA Pending CN116589579A (zh) 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用

Country Status (6)

Country Link
US (2) US12516117B2 (https=)
EP (1) EP3974452A4 (https=)
JP (1) JP7566352B2 (https=)
CN (2) CN113840841B (https=)
AU (1) AU2020277525A1 (https=)
WO (1) WO2020233589A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
AU2021298707A1 (en) * 2020-06-30 2023-02-23 Nanjing IASO Biotechnology Co., Ltd. Fully humanized bispecific chimeric antigen receptor targeting CD19 and CD22 and use thereof
WO2022257984A1 (zh) * 2021-06-08 2022-12-15 南京驯鹿医疗技术有限公司 一种增强型嵌合抗原受体(car)细胞的制备及其应用
CN114891108B (zh) * 2022-05-30 2022-11-15 上海驯鹿生物技术有限公司 一种靶向bcma的全人源抗体及其应用
CN115109140B (zh) * 2022-06-20 2026-04-28 浙江大学医学院附属第一医院 一种靶向特异肿瘤细胞的t细胞受体库构建方法
CN121127253A (zh) 2023-02-28 2025-12-12 朱诺治疗学股份有限公司 治疗系统性自身免疫性疾病的细胞疗法
EP4687962A1 (en) * 2023-03-30 2026-02-11 Cabaletta Bio, Inc. Methods and compositions for treating autoimmune diseases
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses
WO2026050426A2 (en) 2024-08-28 2026-03-05 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor cell therapy for treating autoimmune and neurological diseases
CN119371540B (zh) * 2024-12-10 2025-07-25 星实(上海)生物医药科技有限公司 抗cd19抗体及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002223A2 (en) * 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
CN101233156A (zh) * 2005-06-20 2008-07-30 米德列斯公司 Cd19抗体及其用途
WO2009054863A2 (en) * 2006-12-13 2009-04-30 Medarex, Inc. Human antibodies that bind cd19 and uses thereof
CN104558181A (zh) * 2014-12-31 2015-04-29 四川大学 靶向b淋巴瘤细胞的人源单链抗体
CN106554414A (zh) * 2015-09-18 2017-04-05 科济生物医药（上海）有限公司 抗cd19全人抗体以及靶向cd19的免疫效应细胞
CN107531793A (zh) * 2015-10-13 2018-01-02 优瑞科生物技术公司 对人类cd19具有专一性的抗体药剂和其用途
CN107880128A (zh) * 2017-12-21 2018-04-06 常州费洛斯药业科技有限公司 一种抗cd19的全人源抗体或抗体片段及其方法和应用
CN109293774A (zh) * 2018-10-16 2019-02-01 南京医科大学 特异性结合cd19的全人源化抗体及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021298707A1 (en) 2020-06-30 2023-02-23 Nanjing IASO Biotechnology Co., Ltd. Fully humanized bispecific chimeric antigen receptor targeting CD19 and CD22 and use thereof
WO2022257984A1 (zh) 2021-06-08 2022-12-15 南京驯鹿医疗技术有限公司 一种增强型嵌合抗原受体(car)细胞的制备及其应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002223A2 (en) * 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
CN101233156A (zh) * 2005-06-20 2008-07-30 米德列斯公司 Cd19抗体及其用途
WO2009054863A2 (en) * 2006-12-13 2009-04-30 Medarex, Inc. Human antibodies that bind cd19 and uses thereof
CN101636502A (zh) * 2006-12-13 2010-01-27 梅达雷克斯公司 结合cd19的人类抗体及其用途
CN104558181A (zh) * 2014-12-31 2015-04-29 四川大学 靶向b淋巴瘤细胞的人源单链抗体
CN106554414A (zh) * 2015-09-18 2017-04-05 科济生物医药（上海）有限公司 抗cd19全人抗体以及靶向cd19的免疫效应细胞
CN107531793A (zh) * 2015-10-13 2018-01-02 优瑞科生物技术公司 对人类cd19具有专一性的抗体药剂和其用途
CN107880128A (zh) * 2017-12-21 2018-04-06 常州费洛斯药业科技有限公司 一种抗cd19的全人源抗体或抗体片段及其方法和应用
CN109293774A (zh) * 2018-10-16 2019-02-01 南京医科大学 特异性结合cd19的全人源化抗体及应用

Also Published As

Publication number Publication date
US20220220200A1 (en) 2022-07-14
JP7566352B2 (ja) 2024-10-15
EP3974452A1 (en) 2022-03-30
CN113840841A (zh) 2021-12-24
US20260103517A1 (en) 2026-04-16
WO2020233589A1 (zh) 2020-11-26
CN116589579A (zh) 2023-08-15
JP2022534135A (ja) 2022-07-27
AU2020277525A1 (en) 2022-01-20
WO2020233589A9 (zh) 2021-03-25
US12516117B2 (en) 2026-01-06
EP3974452A4 (en) 2023-08-23
CA3141498A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
CN113840841B (zh) 靶向cd19的全人源抗体及其应用
DK2215121T3 (en) ANTI-mesothelin ANTIBODIES AND USES THEREOF
CN111848800B (zh) Pd-l1单结构域抗体及其用途
JP2002513156A (ja) インターナライズする抗体を選択する方法
JP2020037571A (ja) Ｔｍｃｃ３の阻害による、癌を抑制するための方法
CN116444667B (zh) 一种靶向gdf15的全人源抗体及其应用
KR20220007120A (ko) 항-cd25 항체 및 이의 적용
CN112062851A (zh) 靶向bcma嵌合抗原受体的抗体及其应用
CN112745391B (zh) Pd-l1结合分子
WO2024260440A1 (zh) 一种能够结合lilrb2的抗体或其抗原结合片段
CN110156895B (zh) 一种抗pd-l1抗体或其功能性片段及其用途
CN109293773B (zh) 靶向cd38蛋白的抗体、嵌合抗原受体和药物
CN106084046A (zh) 抗cd3单域抗体
CN106084048A (zh) 抗cd3单域抗体
EP4063387A1 (en) Psma antibody and use thereof
CN113501879A (zh) 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法
CA3141498C (en) Fully human antibody targeting cd19 and application thereof
CN106117359A (zh) 抗cd3单域抗体
CN106146661A (zh) 抗cd3单域抗体
HK40072185A (en) Fully human antibody targeting cd19 and application thereof
CN114891108A (zh) 一种靶向bcma的全人源抗体及其应用
CN109265551B (zh) Cd38抗体、嵌合抗原受体和药物
CN115124620B (zh) 一种能够激活nk细胞的抗体及其应用
JP7738551B2 (ja) Ｐｄ－ｌ１結合分子
CN117264056A (zh) Nrp-1抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 210000 10 / F, building D, phase II, Zhongdan Ecological Life Science Industrial Park, No. 3-1, xinjinhu Road, Jiangbei new district, Nanjing City, Jiangsu Province

Patentee after: Nanjing Reindeer Biotechnology Co.,Ltd.

Address before: 210000 10 / F, building D, phase II, Zhongdan Ecological Life Science Industrial Park, No. 3-1, xinjinhu Road, Jiangbei new district, Nanjing City, Jiangsu Province

Patentee before: NANJING IASO BIOTHERAPEUTICS TECHNOLOGY Co.,Ltd.